Searching for a cure, Improving lives

Pushing for answers from NHS England on PPRS

Posted on: September 7th, 2015 | 0 comments

After receiving a reply to our Freedom of Information Request to Her Majesty’s Treasury, Action Duchenne are continuing investigations into the use of Pharmaceutical Price Regulation Scheme (PPRS) payments by NHS England.

The PPRS  was established to tackle issues of affordability arising from price growth in branded medicine. However, in advance of NHS England’s decision to deny funding approval for 13 treatments in June, including Translarna, James Palmer (Clinical Director of Specialised Commissioning) stated that specialised services were not allocated a boost in resources to deal with the growth in cost for drugs.


However, after a Freedom of Information Request to the Treasury we have determined that NHS England received £796 million from PPRS payments for 2015/16 and that this money has been allocated out to all commissioners who are, “free to invest their allocated funding to deliver improved outcomes as they see fit”.

As such, we have sought clarification from Mr Palmer over how much money specialised services were allocated from this overall sum. If it was a small figure, as his above statement suggests, we have ground to challenge the marginalised position of rare diseases treatments within the PPRS framework. Conversely, if Specialised Services received sufficient funds to tackle questions of affordability, but subsequently failed to do so, then we are in position to challenge NHS England conduct over blatant misuse of funds.

Indeed, NHS England guidance states that PPRS payments should allow the commissioning focus to “shift from cost-saving onto securing better patient outcomes and value”, whilst allowing commissioners to “disengage from cost-containment measures”. It is clear from our experiences with Translarna that this has failed to happen within the commissioning of specialised services.


To read our full letter to James Palmer, please click the link below.

NHS England PPRS Letter


Translarna- What else are we doing? 

– We have further submitted Freedom of Information Requests to NHS England in an attempt to access minutes from their CPAG meetings in June. This will shed light on discussions over Translarna and reveal why the treatment was denied funding.

– These investigatory efforts will allow us to submit a detailed complaint, both to Health Secretary Jeremy Hunt, and the Parliamentary and Health Service Ombudsman, who deal with improper or unfair acts or poor service from central government and NHS England. The conduct and misguidance from NHS England throughout this process must continue to be challenged, and senior figures must be held to account!

– Translarna is still to be evaluated by NICE via their Highly Specialised Technology Route and will be subject to their Evaluation Committee on September 17. Action Duchenne will be in attendance for this meeting which will be additionally informed by our nominated patient expert. We are expecting an interim decision on funding on November 17 and we will continue to do everything possible to ensure this decision is positive.


For more information on the ongoing campaign for access to Translarna, and how you can get involved, please contact, Aaron Revel (Campaigns Officer) on 020 8556 9955 or via

Leave a Reply

Your email address will not be published. Required fields are marked *


Support Action Duchenne with a monthly or one off donation



View our events

View All Events


Join the DMD registry for access to clinical trials


Action Duchenne launches new Research Strategy for Duchenne muscular dystrophy

November 17th, 2017

  Action Duchenne, a leading UK-wide patient and parent-led organisation for Duchenne Muscular Dystrophy, is

Tell me more

Long-term microdystrophin pre-clinical work, moving towards a potential therapy restores muscle function in canines

July 26th, 2017

Promising microdystrophin pre-clinical work, moving towards a potential therapy has shown to restore muscle function

Tell me more

FDA new approach would reduce number of patients treated with placebo

December 11th, 2017

The U.S. Food and Drug Administration (FDA) has published its recommendation for a new approach

Tell me more

Results announced from survey ‘Juggling care and daily life’

December 11th, 2017

The 17th October 2017 was an important date for the rare disease community.  The highlights of the

Tell me more

Duchenne – How do you measure a life?

Living with Duchenne – an animation

Taking charge of Duchenne

wordpress counter

Stay informed with regular updates from Action Duchenne